Lung Cancer References

Last updated: 08 April 2026
Reviewed by
  1. Jhun BW, Park HY, Jeon K, et al. Nodal stations and diagnostic performances of endobronchial ultrasound-guided transbronchial needle aspiration in patients with non-small cell lung cancer. J Korean Med Sci. 2012 Jan;27(1):46-51. doi: 10.3346/jkms.2012.27.1.46. Accessed 15 Oct 2012. PMID: 22219613
  2. Blood Test Detects Lung CancerA blood test that detects a combination of proteins can distinguish between early lung cancer and noncancerous lung nodules, according to a study published in Science Translational Medicine. The two types of nodules are currently difficult to distinguish using imaging. The test showed a 90% negative predictive value in a study of 104 patient samples from three clinical sites. Further validation on 37 samples from a single site showed a 94% negative predictive valueCancer Network; 2013 Oct22 Oct 2013http://www.cancernetwork.com/lung-cancer/blood-test-detects-lung-cancer
  3. MedWormhttp://www.medworm.com/rss/index.php/Cancer-%26-Oncology/6/http://www.medworm.com/rss/medicalfeeds/specialities/Cancer-Oncology.xml
  4. MedWorm http://www.medworm.com/rss/index.php/Respiratory-Medicine/40/ http://www.medworm.com/rss/medicalfeeds/specialities/Respiratory-Medicine-News.xml
  5. Eastern Cooperative Oncology Group. ECOG performance status. http://ecog.dfci.harvard.edu/. Accessed 07 Jul 2010.
  6. Ministry of Health Singapore. Cancer Screening. MOH clinical practice guideline. MOH (Singapore). http://www.moh.gov.sg/. Feb 2010. Accessed 02 Jul 2010.
  7. American Cancer Society. Lung cancer (small cell). http://www.cancer.org/. Jun 2010. Accessed 07 Feb 2010.
  8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 5.2026. NCCN. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. 13 Mar 2026. Accessed 01 Apr 2026.
  9. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 137: Management of lung cancer. Scottish Intercollegiate Guidelines Network (SIGN). http://www.sign.ac.uk/pdf/SIGN137.pdf. Feb 2014. Accessed 10 Sep 2014.
  10. Eberhardt WE, De Ruysscher D, Weder W, et al; Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015 Aug;26(8):1573-1588. http://www.esmo.org/. Accessed 29 Jul 2016. PMID: 25897013
  11. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Mar;160(5):330-338. http://annals.org/data/Journals/AIM/929811/0000605-201403040-00008.pdf. PMID: 24378917
  12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: adult cancer pain. Version 2.2016. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Mar 2016. Accessed 29 Jul 2016.
  13. Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017 Jan;151(1):193-203. doi: 10.1016/j.chest.2016.10.010. PMID: 27780786
  14. Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E; ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi99-105. doi: 10.1093/annonc/mdt178. PMID: 23813929
  15. Thomas KW, Gould MK. Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer. UptoDate. www.uptodate.com. Jul 2016.
  16. Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017 Oct;35(30):3484-3515. doi: 10.1200/JCO.2017.74.6065. PMID: 28806116
  17. National Institute for Health and Clinical Excellence. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer. NICE. http://www.nice.org.uk/. Jul 2015.
  18. Travis WD, Brambilla E, Nicholson AG, et al; WHO Panel. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630. PMID: 26291008
  19. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017 Jul;284(1):228-243. doi: 10.1148/radiol.2017161659. PMID: 28240562
  20. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Lung cancer screening. Version 1.2020. NCCN. https://www.nccn.org/. May 2019.
  21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Palliative care. Version 2.2019. NCCN. https://www.nccn.org/. Feb 2019.
  22. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. European Society of Medical Oncology. https://www.esmo.org/. Sep 2019.
  23. Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019 Feb;30(2):171-210. doi: 10.1093/annonc/mdy554. PMID: 30596843
  24. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: lung cancer screening. Version 1.2026. NCCN. https://www.nccn.org/. 16 Sep 2025. Accessed 12 Apr 2021.
  25. Clinical Therapy Advisor. Non-small cell lung cancer treatment regimens. Clinical Therapy Advisor. https://www.cancertherapyadvisor.com/. 23 Oct 2020. Accessed 12 Apr 2021.
  26. Clinical Therapy Advisor. Small cell lung cancer treatment regimens. Clinical Therapy Advisor. https://www.cancertherapyadvisor.com/. 03 Aug 2020. Accessed 12 Apr 2021.
  27. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Lung cancer screening. Version 1.2022. NCCN. https://www.nccn.org/. 17 Dec 2020.
  28. Yang P. National lung cancer screening program in Taiwan: The TALENT study. J Thorac Oncol. 2021;16(3S):S58-S62. https://www.jto.org/.
  29. Lee H. Medical thoracoscopy (pleuroscopy): Diagnostic and therapeutic applications. UpToDate. https://www.uptodate.com/. 14 Jul 2021.
  30. Thomas KW, Gould MK, Naeger D. Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer . UpToDate. https://www.uptodate.com/. 21 Jun 2022.
  31. Thomas KW, Gould MK. Procedures for tissue biopsy in patients with suspected non-small cell lung cancer. UpToDate. https://www.uptodate.com/. 02 Jun 2022.
  32. Weinberger SE, McDermott S. Diagnostic evaluation of incidental pulmonary nodule. UpToDate. https://www.uptodate.com/. 24 Mar 2022.
  33. Yu MH, Hoffe SE. Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults. UpToDate. https://www.uptodate.com/. 25 Oct 2021.
  34. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: lung cancer screening. Version 1.2024. NCCN. https://www.nccn.org/. 19 Jul 2023.
  35. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 3.2023. NCCN. https://www.nccn.org/. 13 Apr 2023.
  36. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: small cell lung cancer. Version 1.2024. NCCN. https://www.nccn.org/. 05 Sep 2023.
  37. Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022 May;33(5):466-487. doi: 10.1016/j.annonc.2022.02.003. PMID: 35176458
  38. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 4.2023. NCCN. https://www.nccn.org/. 18 Oct 2023.
  39. Stevenson MM. Non-small cell lung cancer (NSCLC) treatment protocols. Medscape. https://reference.medscape.com/. 29 Feb 2024.
  40. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Non-small cell lung cancer. Version 1.2024. NCCN. https://www.nccn.org/. Dec 2023.
  41. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Small cell lung cancer. Version 2.2024. NCCN. https://www.nccn.org/. Nov 2023.
  42. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Non-small cell lung cancer. Version 5.2024. NCCN. https://www.nccn.org/. 23 Apr 2024.
  43. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Small cell lung cancer. Version 3.2024. NCCN. https://www.nccn.org/. 11 Jun 2024.
  44. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022 Mar;17(3):362-387. doi: 10.1016/j.jtho.2021.11.003. PMID: 34808341
  45. Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol. 2024 May:JCO2400581. doi: 10.1200/JCO.24.00581. PMID: 38819031
  46. Zhang PX, Liu FJ, Wang DQ, et al. A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer. J Clin Oncol. 2024 May;42(16):8098. https://doi.org/10.1200/JCO.2024.42.16_suppl.8098.
  47. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 11.2024. NCCN. https://www.nccn.org/. 15 Oct 2024.
  48. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021 Feb;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. PMID: 33581821
  49. Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021 May;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366. PMID: 33792623
  50. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 4.2025. NCCN . https://www.nccn.org/. 23 May 2025.
  51. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: small cell lung cancer. Version 4.2025. NCCN. https://www.nccn.org/. 13 Jan 2025.
  52. Markham A. Savolitinib: first approval. Drugs. 2021 Sep;81(14):1665-1670. doi: 10.1007/s40265-021-01584-0. PMID: 34455538
  53. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): non-small cell lung cancer. Version 7.2025. NCCN. https://www.nccn.org/. 10 Jul 2025.
  54. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): small cell lung cancer. Version 2.2026. NCCN. https://www.nccn.org/. 16 Sep 2025.
  55. National Medical Products Administration (NMPA). The National Medical Products Administration approved the marketing of savolitinib tablets. NMPA. https://www.nmpa.gov.cn/. 23 Jun 2021.
  56. Zer A, Ahn MJ, Barlesi F, et al; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol. 2025 Aug:S0923-7534(25)00923-8. doi: 10.1016/j.annonc.2025.08.003. PMID: 40885528